ReviewDiscover nano2026
Advancements in nanobiosensors for early cancer detection, challenges, treatment, and future prospects: a comprehensive review.
Review in Discover nano, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundCancer is one of the leading causes of global mortality. To reduce treatment costs, improve quality of life and increase survival outcomes for an individual, early detection of cancer is crucial. Advances in nanobiosensors offer point-of-care detection with high specificity and sensitivity for biomarkers associated with tumour detection. Such biosensors also support personalised approaches to cancer treatment. Some nanosensors might be developed as theranostics, where they deliver therapeutic molecules or aid in therapy via mechanisms like photothermal ablation, sonodynamic therapy or precise targeting of therapeutic molecule to the tumor site. A comprehensive review is presented where the latest advances in nanoparticle based sensors are discusses.
aimTo examine emerging nanotechnology-driven biosensing approaches for cancer detection, a comprehensive review that encompass the detailed modus operandi and advantages and disadvantages and advancements in Nanoparticle-based biosensors, Paramagnetic nanoparticle-based biosensor, Quantum dots, Nano-shells-based biosensor, Gold nanoparticle-based biosensor, Nanowire-based biosensors, Nanorods, Carbon Nanotube Based Biosensors, Nanocantilever-based based biosensor, Nanocomposite based biosensors, NanoVelcro based biosensors, Nanozymes, and Amperometric Sensor is presented.
methodThis review is based on a comprehensive analysis of published literature related to advanced nanomaterial-based biosensors for cancer diagnosis. Relevant research articles related to cancer detection, review papers, and reports were collected from scientific databases such as NCBI, PubMed, Web of Science, and Google Scholar. Keywords including nanobiosensors, nanocomposites, nanocantilevers, nanowires, carbon-nanotubes, cancer biomarkers, nanoparticles, aptamer-based sensors, nanomaterials, and nano-shells, were used to access literature. Articles which are published mainly within the last few years were prioritized to highlight recent advancements. Applications of various biosensors in detecting different cancer types also has been given. Only articles those are peer reviewed and published in English literature have been included.
resultStudies based on nanomaterials show that there is significant improvement in cancer detection. Additionally, the technology also enables early diagnosis, accurate imaging with the help of biomarkers, and targeted drug delivery. However, issues such as biocompatibility, clinical testing at a large scale, potential toxicity, and challenges related to its regulation remain some of its key limitations.
conclusionNanotechnology has significantly improved early cancer diagnosis via using highly sensitive and specific nanobiosensors. Despite challenges related to safety, cost, and clinical translation, continued research is essential to realize its full potential in cancer diagnostics and management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.